Date: March 30, 2021

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products, Appendix A – Informed Consent for Immunization
and Appendix E – Management of Biologicals

Part 4 – Biological Products
COVID-19 Vaccines

COVID-19 Vaccine ChAdOx1-S [recombinant] (AstraZeneca/Verity Pharmaceuticals)

- INDICATIONS has been revised to indicate that the vaccines should be used in
  individuals 55 years of age and older. Footnote A has been added to address that
  although the vaccines are authorized for use in those 18 years of age and older, NACI
  has recommended that they not be used in people under 55 years of age due to a safety
  signal identified in Europe. In addition content has been added to mention that the
  product monographs for both vaccines have been updated to include information about
  observed events of thromboembolic/thrombocytopenia.
- DOSES AND SCHEDULE has been revised to read “Adults 55 years of age and older”.
- The ADMINISTRATION section has been revised to indicate that the upper limit for room
  temperature is +30°C to align with the most recent versions (March 24, 2021) of the
  AstraZeneca and COVISHIELD product monographs. The associated footnote C has
  been deleted as both vaccines now have the same upper limit for room temperature.
- ADVERSE EVENTS has been updated to include content regarding the potential risk of
  serious blood clots observed within 4 to 16 days following receipt of the AstraZeneca
  vaccine.

Please remove page numbers: 1-4 dated March 18, 2021
Please add new page numbers: 1-4 dated March 30, 2021
Appendix A: Informed Consent for Immunization

- Section 7.1 Definitions has been revised to include the following content regarding Temporary Substitute Decision Makers (TSDM): “If no one from the above list of substitute decision makers is available or qualified or there is a dispute about who is to be chosen, the health care provider must choose a person, including a person employed in the office of the Public Guardian and Trustee, authorized by the Public Guardian and Trustee.”

Please remove page numbers: 14 & 15 dated October 2019
Please add new page numbers: 14 & 15 dated March 2021

Appendix E – Management of Biologicals

Guidance for Receiving and Handling the Pfizer-BioNTech COVID-19 mRNA Vaccine (including dry ice procedures)

- Content under “Replenishing thermal shipper with dry ice” has been revised to include:
  - the recommended size of dry ice pellets
  - that the thermal shipping container should not be opened for more than one minute at a time.
- The section on “Thawing” has been updated to include the subsection “Handling frozen vials” which provides a link to the COVID-19 Pfizer Vaccine Shipping, Storage, Thawing and Use Guidelines.

Please remove page numbers: 1-12 dated March 10, 2021
Please add new page numbers: 1-12 dated March 30, 2021

Guidance for Receiving and Handling the Moderna COVID-19 mRNA Vaccine

- A link to the COVID-19 Moderna Vaccine Shipping, Thawing and Use Guidelines has been added under “Temperature requirements for shipping and storage upon receipt of the vaccine”.

Please remove page numbers: 1-4 dated March 10, 2021
Please add new page numbers: 1-4 dated March 30, 2021
If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

[Signature]

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:

Provincial Health Officer
Dr. Bonnie Henry

Dr. Reka Gustafson
Vice President, Public Health & Wellness, PHSA & Deputy Provincial Health Officer

Deputy Provincial Health Officer
Dr. Martin Lavoie

BC Ministry of Health, Population & Public Health Division:

Brian Sagar
Senior Director Communicable Disease, Population and Public Health Division

Bernard Achampong
Executive Director, Public Health, Planning and Prevention, Population and Public Health Division